|Bid||3.8800 x 1100|
|Ask||4.1700 x 900|
|Day's Range||3.8400 - 4.0600|
|52 Week Range||2.7400 - 9.7600|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.50|
Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference.
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March ...
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session
Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in...
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress
NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
If you're interested in Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), then you might want to consider its beta (a...
Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB): Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical...
A look at the shareholders of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) can tell us which group is most powerful...
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really...
Jill Milne became the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in 2008. This analysis aims first to...
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.